CliffBio
small molecule

AZASITE

AZITHROMYCIN

Loss of exclusivity—loss of exclusivity
CompanyThea →See this company's full patent-cliff portfolio

Drug detail

Brand nameAZASITE
Active ingredientAZITHROMYCIN
Strength1%
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalApril 2007
Marketing statusRX

More from Thea

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

AZASITE patent cliff — loss of exclusivity — | CliffBio